Phase II Randomized, Double-Blind Study of mFOLFIRINOX Plus Ramucirumab Versus mFOLFIRINOX Plus Placebo in Advanced Pancreatic Cancer Patients (Hoosier Cancer Research Network GI14-198)
Summary
The purpose of this phase II trial is to evaluate the efficacy and safety of FOLFIRINOX plus ramucirumab (Arm A) vs. FOLFIRINOX plus placebo (Arm B) patients with advanced pancreatic cancer, not amenable to curative treatment.
For more information on this trial, please go to https://hoosiercancer.org/clinical-trials/trial/gi14-198/.
General Information
NCT#: NCT02581215
Study ID: HCRN GI14-198
Trial Phase: Phase II
Trial Sponsor: Eli Lilly, Hoosier Cancer Research Network
Therapies Used in This Trial: Fluorouracil, Oxaliplatin, Irinotecan, Leucovorin, FOLFIRINOX, Ramucirumab